The Annual General Meeting held on 6 April 2022 authorised the Board of Directors to decide on the issuance of shares and on the issuance of special rights entitling to shares in one or several issues as follows:
A total maximum of 1,800,000 shares may be issued by virtue of the authorisation (including shares that can be issued based on the special rights) corresponding to approximately 10 per cent of all the shares in the company.
The Board of Directors was authorised to decide on all terms and conditions related to the issuance of shares and the issuance of special rights entitling to shares. The issuance of shares and special rights entitling to shares may also take place in deviation from the shareholders’ pre-emptive subscription right (directed share issue) if there is a weighty financial reason for doing so. The authorisation may then be used for mergers and acquisitions or to finance other business-related investments, to maintain and increase the group’s solvency, to implement an incentive scheme, to expand the ownership base and to develop the capital structure.
The authorisation will be valid for 18 months from the decision of the general meeting i.e. until 6 October 2023.